Abstract
Despite its side-effects, most of which are reversible, effectiveness of hormonal therapy in prostate cancer has been demonstrated. Advantages of intermittent hormonal therapy have been evaluated in a number of phase II clinical tests. As a result, side-effects were shown to decrease and quality of life improved. Preliminary phase III tests failed to detect any negative effect of intermittent hormonal therapy on tumor progression-free survival as compared with continuous hormonal therapy.
MeSH terms
-
Aged
-
Androgen Antagonists / administration & dosage*
-
Androgen Antagonists / adverse effects*
-
Antineoplastic Agents, Hormonal / administration & dosage*
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Biomarkers, Tumor / blood
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Disease-Free Survival
-
Drug Administration Schedule
-
Humans
-
Male
-
Middle Aged
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / immunology
-
Neoplasms, Hormone-Dependent / pathology
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / immunology
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / pathology
-
Quality of Life
-
Survival Analysis
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Biomarkers, Tumor
-
Prostate-Specific Antigen